Biostem Technologies (BSEM) Registration filing summary

Company overview and business model

• Focuses on perinatal tissue-based therapies for advanced wound care and surgical applications, leveraging proprietary processing technologies to support tissue repair and regeneration.

• Product portfolio includes placenta- and umbilical cord-derived allografts in dry, cryopreserved, and shelf-stable formats, targeting chronic wounds and surgical healing.

• Expanded into hospital and surgical markets through the acquisition of BioTissue’s surgical and wound care business, including Neox® and Clarix® product lines and a national sales infrastructure.

• Operates a vertically integrated, FDA-registered, AATB-accredited manufacturing facility in Florida, with plans to internalize manufacturing of acquired products.

• Revenue streams are diversified across physician offices, hospitals, ambulatory surgical centers, and government accounts.

Financial performance and metrics

• For the year ended December 31, 2025, pro forma combined revenue was $76.6 million, with a net loss of $9.3 million; for the three months ended March 31, 2026, revenue was $7.6 million and net loss was $8.0 million.

• Gross profit for 2025 was $60.4 million, with operating expenses of $63.9 million; for Q1 2026, gross profit was $4.6 million, with operating expenses of $12.7 million.

• Significant decline in revenue and gross profit in Q1 2026 compared to prior periods, primarily due to changes in Medicare reimbursement and reduced sales to a major distributor.

• As of March 31, 2026, cash and cash equivalents were $13.7 million, with an accumulated deficit of $29.99 million.

• Substantial doubt exists about the ability to continue as a going concern due to negative cash flows, pricing pressures, and upcoming payment obligations.

Use of proceeds and capital allocation

• No proceeds will be received from the resale of shares by the selling stockholder; all proceeds go to the selling stockholder.

• Recent capital allocation includes $15 million upfront and up to $10 million contingent consideration for the BioTissue acquisition, plus planned royalty payments.

• Plans to finance upcoming obligations, including the $10 million Catalyze product payment, through a mix of debt and equity financing.